Sirtex Medical Inc. announced that it will be featured on an upcoming episode of “The Economic Report” as part of the show’s Medical Innovations for the 21st Century series titled, Leading Developments in Liver Cancer Technologies. The segment focuses on the challenges of treating metastatic liver tumors and the role of SIR-Spheres microspheres in providing patients with a treatment option. The episode will air locally on CNN Headline News/Comcast Cable on June 4 and June 5. Sirtex manufactures SIR-Spheres microspheres, the only FDA-approved microsphere therapy for colorectal liver metastases.
Treatments for liver tumors are a priority among oncology specialists in the Miami-Fort Lauderdale area and across the country. Recently, the role of SIR-Spheres microspheres in treating metastatic liver tumors was highlighted at the international Liver Symposium, a unique physician and patient conference held last month in Chicago, which included attendees from Florida. The symposium was organized by YES founder Suzanne Lindley, a ten year colon cancer survivor whose courageous story is featured in “The Economic Report.” The five minute segment also includes expert commentary from physicians who are helping cancer patients learn about treatment options for advanced liver cancer.
“Sirtex believes this opportunity with “The Economic Report” will help further raise awareness of treatment options available for metastatic liver tumors from colon cancer, including SIR-Spheres microspheres,” said Dr. John Reddington, President of Sirtex Medical Inc. “Too many patients are told that there are simply no treatment options left to consider. Education and increased awareness of existing treatment options are critical in our mission to improve patient survival rates and quality of life.”
At least 60 percent of the nearly 150,000 Americans diagnosed with colorectal cancer every year will see their cancer spread to the liver. Microsphere therapy, using SIR-Spheres microspheres, is a minimally-invasive treatment in which millions of radioactive spheres are infused via a catheter into the liver. The microspheres selectively target liver tumors with a dose of internal radiation up to 40 times higher than conventional radiotherapy while sparing healthy tissue.